Imbalanced bone turnover markers and low bone mineral density in patients with osteonecrosis of the femoral head

  • Lulu Tian
  • Seung-Hoon Baek
  • JinAn Jang
  • Shin-Yoon Kim
Original Paper
  • 17 Downloads

Abstract

Purpose

There have been few studies investigating the cumulative effect of individual factors related to bone metabolism on the systemic balance between bone formation and resorption in patients with osteonecrosis of the femoral head (ONFH). We investigated bone mineral density (BMD) of lumbar spine and bone turnover markers that reflect systemic bone metabolism.

Methods

Two-hundred twenty patients with ONFH were matched to 220 healthy subjects according to age, gender, and body mass index. ONFH patients were divided into steroid-induced (18%), alcoholic (21%), and idiopathic ONFH (61%) and subgroup analysis was performed to exclude the effect of steroid and malnutrition on bone metabolism. We compared lumbar spine bone mineral density (BMD) between groups and measured serum bone-specific alkaline phosphatase (BALP) and urinary deoxypyridinoline/creatinine (Dpd/Cr) ratio.

Results

Logistic regression analysis revealed low spine BMD was significantly associated with each subgroup of ONFH when compared with that of the control group (odds ratio of 2.27, 4.24, and 1.86 in alcoholic, steroid, and idiopathic ONFH, respectively). The mean value of serum BALP (27.02 U/L) was within the normal reference range while average urine Dpd/Cr ratio (6.24 nM/mM) increased in ONFH group when compared with respective reference range.

Conclusion

Spine BMD decreased and urinary Dpd/Cr ratio increased in patients with non-traumatic ONFH. Further studies will be necessary to identify whether non-traumatic ONFH is merely a regional disease confined to the femoral head or may affect systemic bone metabolism.

Keywords

Osteonecrosis of femoral head Bone mineral density Bone turnover makers Bone-specific alkaline phosphatase Deoxypyridinoline/creatinine ratio 

Notes

Acknowledgements

We thank professor Won Kee Lee for statistical analysis.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Sohn WY, Lee SH, Min KK, Nam HW, Kim HJ (1999) Lipid profile in patients with osteonecrosis of the femoral head. J Korean Orthop Assoc 34:1059–1065Google Scholar
  2. 2.
    Ha YC, Koo KH, Hwang SC, Kim JR, Park HB, Kim SR, Kim KM (2002) Thrombotic and fibrinolytic abnormality in nontraumatic osteonecrosis of the femoral head. J Korean Orthop Assoc 37:31–35CrossRefGoogle Scholar
  3. 3.
    Jones JP Jr (1985) Fat embolism and osteonecrosis. Orthop Clin North Am 16:595–633PubMedGoogle Scholar
  4. 4.
    Mont MA, Jones LC, Einhorn TA, Hungerford DS, Reddi AH (1998) Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop Relat Res:S314–335Google Scholar
  5. 5.
    Radke S, Battmann A, Jatzke S, Eulert J, Jakob F, Schutze N (2006) Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res 24:945–952.  https://doi.org/10.1002/jor.20097 CrossRefPubMedGoogle Scholar
  6. 6.
    Karsenty G (2000) How many factors are required to remodel bone? Nat Med 6:970–971.  https://doi.org/10.1038/79655 CrossRefPubMedGoogle Scholar
  7. 7.
    Hernigou P, Beaujean F, Lambotte JC (1999) Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br 81:349–355CrossRefPubMedGoogle Scholar
  8. 8.
    Hernigou P, Beaujean F (1997) Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. J Bone Joint Surg Am 79:1047–1053CrossRefPubMedGoogle Scholar
  9. 9.
    Yeh CH, Chang JK, Ho ML, Chen CH, Wang GJ (2009) Different differentiation of stroma cells from patients with osteonecrosis: a pilot study. Clin Orthop Relat Res 467:2159–2167.  https://doi.org/10.1007/s11999-009-0803-0 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chang JK, Ho ML, Yeh CH, Chen CH, Wang GJ (2006) Osteogenic gene expression decreases in stromal cells of patients with osteonecrosis. Clin Orthop Relat Res 453:286–292.  https://doi.org/10.1097/01.blo.0000238869.99980.b2 CrossRefPubMedGoogle Scholar
  11. 11.
    Tingart M, Beckmann J, Opolka A, Matsuura M, Wiech O, Grifka J, Grassel S (2008) Influence of factors regulating bone formation and remodeling on bone quality in osteonecrosis of the femoral head. Calcif Tissue Int 82:300–308.  https://doi.org/10.1007/s00223-008-9111-z CrossRefPubMedGoogle Scholar
  12. 12.
    Yoo JJ, Song WS, Koo KH, Yoon KS, Kim HJ (2009) Osteogenic abilities of bone marrow stromal cells are not defective in patients with osteonecrosis. Int Orthop 33:867–872.  https://doi.org/10.1007/s00264-008-0524-0 CrossRefPubMedGoogle Scholar
  13. 13.
    Koo KH, Kim R, Kim YS, Ahn IO, Cho SH, Song HR, Park YS, Kim H, Wang GJ (2002) Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol 21:299–303.  https://doi.org/10.1007/s100670200078 CrossRefPubMedGoogle Scholar
  14. 14.
    Matsuo K, Hirohata T, Sugioka Y, Ikeda M, Fukuda A (1988) Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res:115–123Google Scholar
  15. 15.
    World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser 843:1–129Google Scholar
  16. 16.
    Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192–202CrossRefPubMedGoogle Scholar
  17. 17.
    Civitelli R, Armamento-Villareal R, Napoli N (2009) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20:843–851.  https://doi.org/10.1007/s00198-009-0838-9 CrossRefPubMedGoogle Scholar
  18. 18.
    Terreni A, Pezzati P (2012) Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab 9:80–84PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352–364CrossRefPubMedGoogle Scholar
  20. 20.
    Maurel DB, Boisseau N, Benhamou CL, Jaffre C (2012) Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int 23:1–16.  https://doi.org/10.1007/s00198-011-1787-7 CrossRefPubMedGoogle Scholar
  21. 21.
    Hofstaetter JG, Wang J, Yan J, Glimcher MJ (2009) The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits. Osteoarthr Cartil 17:362–370.  https://doi.org/10.1016/j.joca.2008.07.013 CrossRefPubMedGoogle Scholar
  22. 22.
    Chen CH, Chang JK, Lai KA, Hou SM, Chang CH, Wang GJ (2012) Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:1572–1578.  https://doi.org/10.1002/art.33498 CrossRefPubMedGoogle Scholar
  23. 23.
    Agarwala S, Shah S, Joshi VR (2009) The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 91:1013–1018.  https://doi.org/10.1302/0301-620X.91B8.21518 CrossRefPubMedGoogle Scholar
  24. 24.
    Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM (2005) The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87:2155–2159.  https://doi.org/10.2106/jbjs.d.02959 CrossRefPubMedGoogle Scholar
  25. 25.
    Lin T, Yan SG, Cai XZ, Ying ZM (2012) Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int 23:1823–1834.  https://doi.org/10.1007/s00198-011-1797-5 CrossRefPubMedGoogle Scholar

Copyright information

© SICOT aisbl 2018

Authors and Affiliations

  • Lulu Tian
    • 1
  • Seung-Hoon Baek
    • 2
    • 3
  • JinAn Jang
    • 3
  • Shin-Yoon Kim
    • 1
    • 2
    • 3
  1. 1.Musculoskeletal Genome Research CenterKyungpook National University HospitalDaeguSouth Korea
  2. 2.Department of Orthopedic Surgery, School of MedicineKyungpook National UniversityDaeguSouth Korea
  3. 3.Department of Orthopedic SurgeryKyungpook National University HospitalDaeguSouth Korea

Personalised recommendations